Concordantly, reduced expression of AMPH1 was previously shown to be associated with breast cancer metastatic, advanced stage, poor clinical outcome, and Paclitaxel plus 5-fluorouracil/ epirubicin/cyclophosphamide treatment resistance34. Here, AMPH is linked to breast cancer.